Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)

Phase 3CompletedNCT00443677

Gruppo Italiano Studio Linfomi307 enrolled

Overview

The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

307

Conditions

Advanced Hodgkin Disease

Interventions

COPPEBVCAD vs BEACOPP vs ABVDDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed diagnosis of Hodgkin disease * Clinical stage IIB, III, IV * No prior treatment for Hodgkin disease or other malignancy * Age 18-65 year * Good cardiac, pulmunar, renal and hepatic function * Performance status 0-3 (Karnofsky 100- 40) * Written Informed Consent Exclusion Criteria: * HIV positivity * Large cell, anaplastic, CD30+ lymphoma

Locations (1)

Centro Oncologico Modenese

Modena, Italy

Outcomes

Primary Outcomes

To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens

Secondary Outcomes

To compare the results in terms of response, failure free survival and relapse free survival of the three regimens

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.